James Elliott Bradner

USPTO Granted Patents = 61 (Patent Applications = 3)

CIPO Patents = 5 (Patent Applications = 23)

EPO Patents = 16 (Patent Applications = 32)

Average Co-Inventor Count = 3.5

ph-index = 14

Forward Citations = 605(Granted Patents)

Forward Citations (Not Self Cited) = 436(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Boston, MA (US) (2016)
Weston, MA (US) (2015 - 2023)

Company Filing History:

60 out of 1,213

Dana-Farber-Cancer Institute Inc.

Cold Spring Harbor Laboratory

patents

4. 2 out of 473

Colorado State University Research Foundation

patents

5. 2 out of 370

University of Notre Dame Du Lac

patents

6. 2 out of 315

Whitehead Institute for Biomedical Research

patents

7. 1 out of 602

Baylor College of Medicine

patents

8. 1 out of 1,565

University of Massachusetts

patents

9. 1 out of 52

Enzon Pharmaceuticals, Inc.

patents

10. 1 out of 447

The Broad Institute, Inc.

patents

11. 1 out of 1,388

The Brigham and Women's Hospital, Inc.

patents

12. 1 out of 2,902

The General Hospital Corporation

patents

13. 1 out of 1,041

Children's Medical Center Corporation

patents

14. 1 out of 293

H. Lee Moffitt Cancer Center and Research Institute, Inc.

where one patent can have more than one assignee

Years Active: 2015-2025

Loading Chart...

Areas of Expertise:

Cancer Treatment

Targeted Protein Degradation

Bromodomain Inhibitors

Chimeric Antigen Receptors

EZH2 Inhibitors

Histone Deacetylase Inhibitors

Ribosomal Disorders

TRIM24 Inhibitors

Diazepane Derivatives

Combination Therapy

Immunotherapy

Protein Kinase Inhibitors

61 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12441685 - Compounds and methods for treating cancer (2025-10-14),

2. 11845728 - Compounds and methods for treating cancer (2023-12-19),

3. 11666580 - Mechanism of resistance to bet bromodomain inhibitors (2023-06-06),

4. 11583586 - Methods to induce targeted protein degradation through bifunctional molecules (2023-02-21),

5. 11578075 - Degradation of protein kinases by conjugation of protein kinase inhibitors with E3 ligase ligand and methods of use (2023-02-14),

6. 11446309 - Combination therapy for cancer using bromodomain and extra-terminal (BET) protein inhibitors (2022-09-20),

7. 11406645 - Acetamide thienotriazolodiazepines and uses thereof (2022-08-09),

8. 11311609 - Regulating chimeric antigen receptors (2022-04-26),

9. 11306105 - Cyano thienotriazolodiazepines and uses thereof (2022-04-19),

10. 11293023 - Tunable endogenous protein degradation (2022-04-05),

11. 11285218 - Degradation of bromodomain-containing protein 9 (BRD9) by conjugation of BRD9 inhibitors with E3 ligase ligand and methods of use (2022-03-29),

12. 11236082 - EZH2 inhibitors and uses thereof (2022-02-01),

13. 11059801 - Methods to induce targeted protein degradation through bifunctional molecules (2021-07-13),

14. 11046954 - Targeted protein degradation to attenuate adoptive T-cell therapy associated adverse inflammatory responses (2021-06-29),

15. 10980808 - Calmodulin inhibitors, Chk2 inhibitors and RSK inhibitors for the treatment of ribosomal disorders and ribosomapathies (2021-04-20),

Title: The Innovative Journey of James Elliott Bradner

Introduction: James Elliott Bradner, a pioneering inventor hailing from Weston, MA, has made significant contributions to the field of innovations and patents with his groundbreaking work.

Latest Patents: Bradner's latest patents showcase his commitment to pushing the boundaries of technology and science, with a focus on advancements in biotechnology and medical devices.

Career Highlights: With a career spanning over two decades, Bradner has established himself as a leading figure in the world of inventions. His innovative spirit and dedication have led to the development of numerous groundbreaking technologies that have revolutionized various industries.

Collaborations: Throughout his career, Bradner has collaborated with top research institutions, universities, and companies to bring his inventions to life. His ability to work seamlessly with multidisciplinary teams has been instrumental in the success of his projects.

Conclusion: James Elliott Bradner's relentless pursuit of innovation and his passion for creating transformative technologies have solidified his position as a trailblazing inventor. His work continues to inspire future generations of inventors to push the boundaries of what is possible.

This text is generated by artificial intelligence and may not be accurate.